Newamsterdam Pharma Company N.V. (NAMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Sales | 32 | 348 | 19,145 | 2,978 | 12,772 |
| Gross Profit | 32 | 348 | 19,145 | 2,978 | 12,772 |
| Operating Expenses | 66,012 | 55,491 | 54,780 | 71,903 | 56,001 |
| Operating Income | -65,980 | -55,143 | -35,635 | -68,925 | -43,229 |
| Other Income | -8,943 | -16,862 | 18,271 | 29,398 | -48,948 |
| Pre-tax Income | -74,923 | -72,005 | -17,364 | -39,527 | -92,177 |
| Net Income Continuous | -74,923 | -72,005 | -17,364 | -39,527 | -92,177 |
| Net Income | $-74,923 | $-72,005 | $-17,364 | $-39,527 | $-92,177 |
| EPS Basic Total Ops | -0.62 | -0.61 | -0.15 | -0.34 | -0.91 |
| EPS Basic Continuous Ops | -0.63 | -0.61 | -0.15 | -0.34 | -0.91 |
| EPS Diluted Total Ops | -0.62 | -0.61 | -0.15 | -0.34 | -0.91 |
| EPS Diluted Continuous Ops | -0.63 | -0.61 | -0.15 | -0.34 | -0.91 |
| EPS Diluted Before Non-Recurring Items | -0.63 | -0.41 | -0.15 | -0.49 | -0.95 |
| EBITDA(a) | $-65,921 | $-55,079 | $-35,590 | $-68,873 | $-43,178 |